+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Human Microbiome Therapeutics Market 2020-2024 - Product Image

Global Human Microbiome Therapeutics Market 2020-2024

  • ID: 5031157
  • Report
  • May 2020
  • Region: Global
  • 120 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Dow Inc.
  • ENTEROME SA
  • Johnson & Johnson
  • Kaleido Biosciences Inc.
  • PureTech Health Plc
  • MORE
Global Human Microbiome Therapeutics Market 2020-2024

The human microbiome therapeutics market is poised to grow by USD 276.93 mn during 2020-2024 progressing at a CAGR of 15% during the forecast period. This report on the human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of chronic diseases and robust pipeline. In addition, growing prevalence of chronic diseases is anticipated to boost the growth of the market as well.

The human microbiome therapeutics market analysis includes application segment and geographic landscapes

The human microbiome therapeutics market is segmented as below:

By Application
  • Gastrointestinal disorders
  • Immunological conditions
  • Others
By Geographic Landscapes
  • North America
  • Europe
  • APAC
  • ROW
This study identifies the side effects of existing treatment as one of the prime reasons driving the human microbiome therapeutics market growth during the next few years.

The human microbiome therapeutics market covers the following areas:
  • Human microbiome therapeutics market sizing
  • Human microbiome therapeutics market forecast
  • Human microbiome therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human microbiome therapeutics market vendors that include Bristol-Myers Squibb Co., Dow Inc., ENTEROME SA, Ferring Pharmaceuticals AS, Johnson & Johnson, Kaleido Biosciences Inc., PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd.. Also, the human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The research presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Dow Inc.
  • ENTEROME SA
  • Johnson & Johnson
  • Kaleido Biosciences Inc.
  • PureTech Health Plc
  • MORE
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Application
  • Market segments
  • Comparison by Application
  • Gastrointestinal disorders - Market size and forecast 2019-2024
  • Immunological conditions - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by application
Customer landscape

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Vendor landscape
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Dow Inc.
  • ENTEROME SA
  • Ferring Pharmaceuticals AS
  • Johnson & Johnson
  • Kaleido Biosciences Inc.
  • PureTech Health Plc
  • Second Genome Therapeutics
  • Seres Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019 - 2024 ($ million)
13: Global market: Year-over-year growth 2019 - 2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: Application - Market share 2019-2024 (%)
22: Comparison by Application
23: Gastrointestinal disorders - Market size and forecast 2019-2024 ($ million)
24: Gastrointestinal disorders - Year-over-year growth 2019-2024 (%)
25: Immunological conditions - Market size and forecast 2019-2024 ($ million)
26: Immunological conditions - Year-over-year growth 2019-2024 (%)
27: Others - Market size and forecast 2019-2024 ($ million)
28: Others - Year-over-year growth 2019-2024 (%)
29: Market opportunity by Application
30: Customer landscape
31: Market share by geography 2019-2024 (%)
32: Geographic comparison
33: North America - Market size and forecast 2019-2024 ($ million)
34: North America - Year-over-year growth 2019-2024 (%)
35: Europe - Market size and forecast 2019-2024 ($ million)
36: Europe - Year-over-year growth 2019-2024 (%)
37: APAC - Market size and forecast 2019-2024 ($ million)
38: APAC - Year-over-year growth 2019-2024 (%)
39: ROW - Market size and forecast 2019-2024 ($ million)
40: ROW - Year-over-year growth 2019-2024 (%)
41: Key leading countries
42: Market opportunity by geography ($ million)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: Bristol-Myers Squibb Co. - Overview
50: Bristol-Myers Squibb Co. - Business segments
51: Bristol-Myers Squibb Co. - Key offerings
52: Bristol-Myers Squibb Co. - Key customers
53: Bristol-Myers Squibb Co. - Segment focus
54: Dow Inc. - Overview
55: Dow Inc. - Business segments
56: Dow Inc. - Key offerings
57: Dow Inc. - Key customers
58: Dow Inc. - Segment focus
59: ENTEROME SA - Overview
60: ENTEROME SA - Product and service
61: ENTEROME SA - Key offerings
62: ENTEROME SA - Key customers
63: ENTEROME SA - Segment focus
64: Ferring Pharmaceuticals AS - Overview
65: Ferring Pharmaceuticals AS - Product and service
66: Ferring Pharmaceuticals AS - Key offerings
67: Ferring Pharmaceuticals AS - Key customers
68: Ferring Pharmaceuticals AS - Segment focus
69: Johnson & Johnson - Overview
70: Johnson & Johnson - Business segments
71: Johnson & Johnson - Key offerings
72: Johnson & Johnson - Key customers
73: Johnson & Johnson - Segment focus
74: Kaleido Biosciences Inc. - Overview
75: Kaleido Biosciences Inc. - Product and service
76: Kaleido Biosciences Inc. - Key offerings
77: Kaleido Biosciences Inc. - Key customers
78: Kaleido Biosciences Inc. - Segment focus
79: PureTech Health Plc - Overview
80: PureTech Health Plc - Business segments
81: PureTech Health Plc - Key offerings
82: PureTech Health Plc - Key customers
83: PureTech Health Plc - Segment focus
84: Second Genome Therapeutics - Overview
85: Second Genome Therapeutics - Product and service
86: Second Genome Therapeutics - Key offerings
87: Second Genome Therapeutics - Key customers
88: Second Genome Therapeutics - Segment focus
89: Seres Therapeutics Inc. - Overview
90: Seres Therapeutics Inc. - Product and service
91: Seres Therapeutics Inc. - Key offerings
92: Seres Therapeutics Inc. - Key customers
93: Seres Therapeutics Inc. - Segment focus
94: Takeda Pharmaceutical Co. Ltd. - Overview
95: Takeda Pharmaceutical Co. Ltd. - Product and service
96: Takeda Pharmaceutical Co. Ltd. - Key offerings
97: Takeda Pharmaceutical Co. Ltd. - Key customers
98: Takeda Pharmaceutical Co. Ltd. - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Dow Inc.
  • ENTEROME SA
  • Johnson & Johnson
  • Kaleido Biosciences Inc.
  • PureTech Health Plc
  • MORE
The publisher recognizes the following companies as the key players in the global human microbiome therapeutics market: Bristol-Myers Squibb Co., Dow Inc., ENTEROME SA, Ferring Pharmaceuticals AS, Johnson & Johnson, Kaleido Biosciences Inc., PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is side effects of existing treatment ."

According to the report, one of the major drivers for this market is the growing prevalence of chronic diseases.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bristol-Myers Squibb Co.
  • Dow Inc.
  • ENTEROME SA
  • Ferring Pharmaceuticals AS
  • Johnson & Johnson
  • Kaleido Biosciences Inc.
  • PureTech Health Plc
  • Second Genome Therapeutics
  • Seres Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll